Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Betaxolol differs from timolol in that it:
A. Is a β1 selective blocker
B. Is more efficacious in glaucoma
C. Produces less ocular side effects
D. Is longer acting
by

1 Answer

Answer :

A. Is a β1 selective blocker
by

Related questions

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Description : Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Last Answer : D. Levobunolol

Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Description : Select the longer acting ocular beta blocker: A. Timolol B. Betaxolol C. Cartiolol D. Levobunolol

Last Answer : D. Levobunolol

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Timolol eye drops are preferred over pilocarpine eye drops by glaucoma patients because: A. Timolol is more effective than pilocarpine B. Timolol acts by enhancing uveo-scleral outflow C. Timolol produces less ocular side effects D. There are no contraindications to timolol

Description : Timolol eye drops are preferred over pilocarpine eye drops by glaucoma patients because: A. Timolol is more effective than pilocarpine B. Timolol acts by enhancing uveo-scleral outflow C. Timolol produces less ocular side effects D. There are no contraindications to timolol

Last Answer : C. Timolol produces less ocular side effects

Timolol eye drops are preferred over pilocarpine eye drops by glaucoma patients because: A. Timolol is more effective than pilocarpine B. Timolol acts by enhancing uveo-scleral outflow C. Timolol produces less ocular side effects D. There are no contraindications to timolol

Description : Timolol eye drops are preferred over pilocarpine eye drops by glaucoma patients because: A. Timolol is more effective than pilocarpine B. Timolol acts by enhancing uveo-scleral outflow C. Timolol produces less ocular side effects D. There are no contraindications to timolol

Last Answer : C. Timolol produces less ocular side effects

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

To be used as a topically applied ocular beta blocker a drug should have the following properties except: A. Strong local anaesthetic activity B. High lipophilicity C. High ocular capture D. Low systemic activity

Description : To be used as a topically applied ocular beta blocker a drug should have the following properties except: A. Strong local anaesthetic activity B. High lipophilicity C. High ocular capture D. Low systemic activity

Last Answer : A. Strong local anaesthetic activity

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Which of the following is a selective α1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Description : Which of the following is a selective α1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Last Answer : D. Tamsulosin

Which of the following is a selective α 1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Description : Which of the following is a selective α 1A receptor blocker that affords symptomatic relief in benign prostatic hypertrophy without producing significant fall in blood pressure: A. Terazosin B. Doxazosin C. Trimazosin D. Tamsulosin

Last Answer : D. Tamsulosin

The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are incompletely absorbed after oral administration C. They are devoid of CNS and ocular effects D. Dose to dose they are more potent than atropine

Description : The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are ... of CNS and ocular effects D. Dose to dose they are more potent than atropine

Last Answer : C. They are devoid of CNS and ocular effects

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Choose the correct statement about drotaverine: A. It is a smooth muscle antispasmodic acting by non-anticholinergic mechanisms B. It is a papaverine congener used in peripheral vascular diseases C. It is a synthetic atropine substitute used to control diarrhoea D. It is a M1/M3 selective antagonist used for spastic constipation

Description : Choose the correct statement about drotaverine: A. It is a smooth muscle antispasmodic acting by non-anticholinergic mechanisms B. It is a papaverine congener used in peripheral vascular diseases C. It ... used to control diarrhoea D. It is a M1/M3 selective antagonist used for spastic constipation

Last Answer : A. It is a smooth muscle antispasmodic acting by non-anticholinergic mechanisms

Edrophonium is more suitable for differentiating myasthenic crisis from cholinergic crisis because of its: A. Shorter duration of action B. Longer duration of action C. Direct action on muscle end-plate D. Selective inhibition of true cholinesterase

Description : Edrophonium is more suitable for differentiating myasthenic crisis from cholinergic crisis because of its: A. Shorter duration of action B. Longer duration of action C. Direct action on muscle end-plate D. Selective inhibition of true cholinesterase

Last Answer : A. Shorter duration of action

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Pyridostigmine differs from neostigmine in that (a) More potent orally (b) Longer acting (c) Less muscarinic side effects (d) All of the above

Description : Pyridostigmine differs from neostigmine in that (a) More potent orally (b) Longer acting (c) Less muscarinic side effects (d) All of the above

Last Answer : Ans: B

The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Description : The most efficacious inhibitor of catecholamine synthesis in the body is: A. α-methyl-p-tyrosine B. α-methyldopa C. α-methyl-norepinephrine D. Entacapone

Last Answer : A. α-methyl-p-tyrosine

ndapamide differs from other diuretics in that: A. It has selective antihypertensive action at doses which cause little diuresis B. It is a more efficacious antihypertensive C. Its antihypertensive action develops more rapidly D. All of the above

Description : ndapamide differs from other diuretics in that: A. It has selective antihypertensive action at doses which cause little diuresis B. It is a more efficacious antihypertensive C. Its antihypertensive action develops more rapidly D. All of the above

Last Answer : A. It has selective antihypertensive action at doses which cause little diuresis

Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Description : Dexamethasone differs from prednisolone in that it is: A. Longer acting B. More potent C. More selective D. All of the above

Last Answer : D. All of the above

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α-reductase inhibitor used to reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Description : Choose the correct statement about latanoprost: A. It is a PGF2α derivative used in glaucoma B. It is a selective α1 blocker used in benign hypertrophy of prostate C. It is a 5-α- ... reduce the size of enlarged prostate gland D. It is a PGE2 analogue used intravaginally for cervical priming

Last Answer : A. It is a PGF2α derivative used in glaucoma

The following disease is worsened by propranolol: A. Glaucoma B. Raynaud’s disease C. Benign prostatic hypertrophy D. Parkinsonism

Description : The following disease is worsened by propranolol: A. Glaucoma B. Raynaud’s disease C. Benign prostatic hypertrophy D. Parkinsonism

Last Answer : B. Raynaud’s disease

Select the diuretic that is most effective in acute congestive glaucoma: A. Indapamide B. Amiloride C. Mannitol D. Furosemide

Description : Select the diuretic that is most effective in acute congestive glaucoma: A. Indapamide B. Amiloride C. Mannitol D. Furosemide

Last Answer : C. Mannitol

Pilocarpine is used for: A. Glaucoma B. Paralytic ileus C. Urinary retention D. All of the above

Description : Pilocarpine is used for: A. Glaucoma B. Paralytic ileus C. Urinary retention D. All of the above

Last Answer : A. Glaucoma

The following disease is worsened by propranolol: A. Glaucoma B. Raynaud’s disease C. Benign prostatic hypertrophy D. Parkinsonism

Description : The following disease is worsened by propranolol: A. Glaucoma B. Raynaud’s disease C. Benign prostatic hypertrophy D. Parkinsonism

Last Answer : B. Raynaud’s disease

Select the diuretic that is most effective in acute congestive glaucoma: A. Indapamide B. Amiloride C. Mannitol D. Furosemide

Description : Select the diuretic that is most effective in acute congestive glaucoma: A. Indapamide B. Amiloride C. Mannitol D. Furosemide

Last Answer : C. Mannitol

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Acetylcholine has no therapeutic application because: A. None of its actions are beneficial in any condition B. Its effects are transient C. It produces wide spread actions affecting many organs D. Both ‘B’ and ‘C’ are correct

Description : Acetylcholine has no therapeutic application because: A. None of its actions are beneficial in any condition B. Its effects are transient C. It produces wide spread actions affecting many organs D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Cholinergic muscarinic receptor stimulation produces the following effects except: A. Sweating B. Rise in blood pressure C. Bradycardia D. Urination

Description : Cholinergic muscarinic receptor stimulation produces the following effects except: A. Sweating B. Rise in blood pressure C. Bradycardia D. Urination

Last Answer : B. Rise in blood pressure

Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Description : Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris

Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Description : Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Last Answer : B. It hydrolyses acetylcholine at a slower rate

Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Description : Pseudocholinesterase differs from true cholinesterase in that: A. It does not hydrolyse acetylcholine B. It hydrolyses acetylcholine at a slower rate C. It is more susceptible to inhibition by physostigmine D. It is the only form of circulating cholinesterase

Last Answer : B. It hydrolyses acetylcholine at a slower rate

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action